alvarez-Garcia, JesusGarcia-Osuna, AlvaroVives-Borras, MiquelFerrero-Gregori, AndreuMartinez-Selles, ManuelVazquez, RafaelGonzalez-Juanatey, Jose R.Rivera, MiguelSegovia, JavierPascual-Figal, DomingoBover, RamonBascompte, RamonDelgado, JuanGrau Sepulveda, AndresBardaji, AlfredoPerez-Villa, FelixZamorano, Jose LuisCrespo-Leiro, MarisaSanchez, Pedro LuisOrdonez-Llanos, JordiCinca, JuanSpanish Heart Failure Network2025-01-072025-01-072021-10-22https://hdl.handle.net/10668/25217Introduction and Objectives: Most multi-biomarker strategies in acute heart failure (HF) have only measured biomarkers in a single-point time. This study aimed to evaluate the prognostic yielding of NT-proBNP, hsTnT, Cys-C, hs-CRP, GDF15, and GAL-3 in HF patients both at admission and discharge.Methods: We included 830 patients enrolled consecutively in a prospective multicenter registry. Primary outcome was 12-month mortality. The gain in the C-index, calibration, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) was calculated after adding each individual biomarker value or their combination on top of the best clinical model developed in this study (C-index 0.752, 0.715-0.789) and also on top of 4 currently used scores (MAGGIC, GWTG-HF, Redin-SCORE, BCN-bioHF).Results: After 12-month, death occurred in 154 (18.5%) cases. On top of the best clinical model, the addition of NT-proBNP, hs-CRP, and GDF-15 above the respective cutoff point at admission and discharge and their delta during compensation improved the C-index to 0.782 (0.747-0.817), IDI by 5% (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/biomarker (BM)panel (C33)acute heart failure (AHF)risk stratificationprognosisBrain natriuretic peptideSensitivity troponin-tFamily-member st2Prognostic valueTerm mortalityBiomarkersPredictionGuidelinesScoreHospitalizationresearch article34744758open access10.3389/fphys.2021.7088901664-042Xhttps://www.frontiersin.org/articles/10.3389/fphys.2021.708890/pdf716498400001